Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor

Growth Factors

Volumn 28, Issue 3, 2010, Pages 211-220

  Kernt, M ^a   Liegl, R G ^a   Rueping, J ^a   Neubauer, A S ^a   Haritoglou, C ^a   Lackerbauer, C A ^a   Eibl, K H ^a   Ulbig, M W ^a   Kampik, A ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bevacizumab; Glia; Multikinase inhibitors; Neovascularization; Ranibizumab

Indexed keywords

MESSENGER RNA; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; SORAFENIB; VASCULOTROPIN;

ARTICLE; ASTROCYTE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLIA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; LIGHT EXPOSURE; NEUROPROTECTION; OPTIC NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RETINA CELL; RETINA NEOVASCULARIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WHITE LIGHT;

ADULT; AGED; ASTROCYTES; BENZENESULFONATES; CELL SURVIVAL; HUMANS; LIGHT; MIDDLE AGED; OPTIC DISK; PLATELET-DERIVED GROWTH FACTOR; PREGNANCY PROTEINS; PROTEIN KINASE INHIBITORS; PYRIDINES; RETINA; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952471137     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977191003604505     Document Type: Article

References (53)

1. Adnane L, Trail PA, Taylor I, Wilhelm SM. 2006. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407:597-612.
2. Aiello LP. 2008. Targeting intraocular neovascularization and edema-one drop at a time. N Engl J Med 359 (9):967-969.
3. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE. 1995. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92 (23):10457-10461.
4. Andrae J, Gallini R, Betsholtz C. 2008. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22 (10):1276-1312.
5. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, Simpson IA. 2006. Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease. Diabetes 55 (9):2401-2411.
6. Behzadian MA, Wang XL, Al-Shabrawey M, Caldwell RB. 1998. Effects of hypoxia on glial cell expression of angiogenesis regulating factors VEGF and TGF-beta. Glia 24 (2):216-225.
7. Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, Tong P, Lutty GA. 2006. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res 826 (1):99-110.
8. Buniatian GH. 1997. Further similarities between astrocytes and perisinusoidal stellate cells of liver (Ito cells): Colocalization of desmin and glial fibrillary acidic protein in astroglial primary cultures. Biol Cell 89 (3):169-177.
9. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M. 2006. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98 (5):326-334.
10. Chan-Ling TL, Halasz P, Stone J. 1990. Development of retinal vasculature in the cat: Processes and mechanisms. Curr Eye Res 9 (5):459-478.
11. Ciulla TA, Rosenfeld PJ. 2009. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol 20 (3):166-174.
12. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P. 2004. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122 (4):477-485. (Pubitemid 38456282)
13. Crocker DJ, Murad TM, Geer JC. 1970. Role of the pericyte in wound healing. An ultrastructural study. Exp Mol Pathol 13 (1):51-65.
14. Das A, McGuire PG. 2003. Retinal and choroidal angiogenesis: Pathophysiology and strategies for inhibition. Prog Retin Eye Res 22 (6):721-748.
15. Diago T, Pulido JS, Molina JR, Collett LC, Link TP, Ryan EH, Jr. 2008. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. Mayo Clin Proc 83 (2):231-234.
16. Dorrell MI, Aguilar E, Jacobson R, Trauger SA, Friedlander J, Siuzdak G, Friedlander M. 2009. Maintaining retinal astrocytes normalizes revascularization and prevents vascular pathology associated with oxygen-induced retinopathy. Glia.
17. Ehrlich R, Harris A, Kheradiya NS, Winston DM, Ciulla TA, Wirostko B. 2008. Age-related macular degeneration and the aging eye. Clin Interv Aging 3 (3):473-482.
18. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P. 2004. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 18 (2):338-340.
19. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. 2007. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2):125-134.
20. Esposito G, De Filippis D, Cirillo C, Sarnelli G, Cuomo R, Iuvone T. 2006. The astroglial-derived S100beta protein stimulates the expression of nitric oxide synthase in rodent macrophages through p38 MAP kinase activation. Life Sci 78 (23):2707-2715.
21. Gardner TW, Lieth E, Khin SA, Barber AJ, Bonsall DJ, Lesher T, Rice K, Brennan WA, Jr. 1997. Astrocytes increase barrier properties and ZO-1 expression in retinal vascular endothelial cells. Invest Ophthalmol Vis Sci 38 (11):2423-2427.
22. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. 2003. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161:1163-1177.
23. Ikuno Y, Hibino S, Bando H, Kawasaki Y, Nakamura T, Tano Y. 2002. Retinal glial cells stimulate microvascular pericyte proliferation via fibroblast growth factor and platelet-derived growth factor in vitro. Jpn J Ophthalmol 46 (4):413-418.
24. Jager RD, Mieler WF, Miller JW. 2008. Age-related macular degeneration. N Engl J Med 358 (24):2606-2617.
25. Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT. 2006. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168 (6):2036-2053.
26. Kernt M, Hirneiss C, Neubauer AS, Lackerbauer CA, Eibl KH, Wolf A, Ulbig M, Kampik A. 2009. Protective effect of blue light-absorbing IOLs on the human retinal pigment epithelium. Ophthalmol [Epub ahead of print].
27. Kernt M, Neubauer AS, Liegl R, Eibl KH, Alge CS, Lackerbauer CA, Ulbig MW, Kampik A. 2009. Cytoprotective effects of a blue light-filtering intraocular lens on human retinal pigment epithelium by reducing phototoxic effects on vascular endothelial growth factor-alpha, Bax, and Bcl-2 expression. J Cataract Refract Surg 35 (2):354-362.
28. Kernt M, Neubauer AS, Ulbig MW, Kampik A, Welge-Lussen U. 2008. In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. J Cataract Refract Surg 34 (3):480-488.
29. Kernt M, Staehler M, Stief C, Kampik A, Neubauer AS. 2008. Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. Acta Ophthalmol 86 (4):456-458.
30. Kobayashi S, Vidal I, Pena JD, Hernandez MR. 1997. Expression of neural cell adhesion molecule (NCAM) characterizes a subpopulation of type 1 astrocytes in human optic nerve head. Glia 20 (3):262-273.
31. Lambert W, Agarwal R, Howe W, Clark AF, Wordinger RJ. 2001. Neurotrophin and neurotrophin receptor expression by cells of the human lamina cribrosa. Invest Ophthalmol Vis Sci 42:2315-2323.
32. Laterra J, Guerin C, Goldstein GW. 1990. Astrocytes induce neural microvascular endothelial cells to form capillary-like structures in vitro. J Cell Physiol 144 (2):204-215.
33. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. 2006. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66 (24):11851-11858.
34. Miyake K, Ichihashi S, Shibuya Y, Ota I, Miyake S, Terasaki H. 1999. Blood-retinal barrier and autofluorescence of the posterior polar retina in long-standing pseudophakia. J Cataract Refract Surg 25 (7):891-897.
35. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1-2):55-63.
36. Penfold PL, Provis JM, Furby JH, Gatenby PA, Billson FA. 1990. Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 228 (3):270-274.
37. Penfold PL, Provis JM, Madigan MC, van Driel D, Billson FA. 1990. Angiogenesis in normal human retinal development: The involvement of astrocytes and macrophages. Graefes Arch Clin Exp Ophthalmol 228 (3):255-263.
38. Peyman GA, Fiscella R, Conway M. 2009. Combination angiostatic therapies: Current status. Retina 29 (6 Suppl):S18-S20.
39. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ. 2006. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (16):2505-2512. (Pubitemid 46630627)
40. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. 2006. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (14):1419-1431.
41. Schlingemann RO. 2004. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 242 (1):91-101.
42. Schlingemann RO, Oosterwijk E, Wesseling P, Rietveld FJ, Ruiter DJ. 1996. Aminopeptidase a is a constituent of activated pericytes in angiogenesis. J Pathol 179 (4):436-442.
43. Seo MS, Okamoto N, Vinores MA, Vinores SA, Hackett SF, Yamada H, Yamada E, Derevjanik NL, LaRochelle W, Zack DJ, Campochiaro PA. 2000. Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. Am J Pathol 157 (3):995-1005.
44. Spaide RF. 2009. Rationale for combination therapy in age-related macular degeneration. Retina 29 (6 Suppl):S5-S7.
45. Stone J, Itin A, Alon T, Péer J, Gnessin H, Chan-Ling T, Keshet E. 1995. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 15 (7 Pt 1):4738-4747.
46. Werner S, Grose R. 2003. Regulation of wound healing by growth factors and cytokines. Physiol Rev 83 (3):835-870.
47. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. 2008. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7 (19):3129-3140.
48. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (19):7099-7109.
49. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. 2003. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22 (1):1-29.
50. Yang J, Yang P, Tezel G, Patil RV, Hernandez MR, Wax MB. 2001. Induction of HLA-DR expression in human lamina cribrosa astrocytes by cytokines and simulated ischemia. Invest Ophthalmol Vis Sci 42 (2):365-371.
51. Zhang Y, Stone J. 1997. Role of astrocytes in the control of developing retinal vessels. Invest Ophthalmol Vis Sci 38 (9):1653-1666.
52. Zhou J, Cai B, Jang YP, Pachydaki S, Schmidt AM, Sparrow JR. 2005. Mechanisms for the induction of HNE-MDA- and AGE-adducts, RAGE and VEGF in retinal pigment epithelial cells. Exp Eye Res 80 (4):567-580.
53. Zimmer DB, Cornwall EH, Landar A, Song W. 1995. The S100 protein family: History, function, and expression. Brain Res Bull 37 (4):417-429.